MAP2K7 and hepatocellular carcinoma: Since PEG3 was demonstrated as a biomarker of Mek/Erk/ROS/mTOR-driven hepatocarcinogenesis in response to KrasG12D mutation and Tsc1 insufficiency in murine models, we attempted to determine whether this biomarker was also applicable to HCC patients.